AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, the SAA1 polymorphism was confirmed as a susceptibility factor for AA amyloidosis irrespective of the type of the disease.
|
29364741 |
2018 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum amyloid A1 (SAA1) is an apolipoprotein that binds to the high-density lipoprotein (HDL) fraction of the serum and constitutes the fibril precursor protein in systemic AA amyloidosis.
|
28637682 |
2017 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein.We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.Thirty-seven patients with AA amyloidosis were started an anti-TNF for AA amyloidosis between March 2001 and June 2008 and followed until May 2016 unless deceased.
|
28834898 |
2017 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell-to-cell transfer of SAA1 protein in a cell culture model of systemic AA amyloidosis.
|
28361953 |
2017 |
AA amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Monitoring SAA level in attack-free FMF patients is recommended in order to adjust colchicine dose, and minimize the risk of AA amyloidosis.
|
27838405 |
2017 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with FMF or a rheumatic disease and the SAA1 α/α genotype had a relative risk of 4.86 and 2.53, respectively, for developing an AA amyloidosis.
|
25376380 |
2015 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the four human SAA genotypes, SAA1 is most commonly associated with AA amyloidosis.
|
24440699 |
2014 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
His mother was also a carrier of the SAA1.3 allele, which is not only a univariate predictor of survival but also a risk factor for the association of AA amyloidosis with rheumatoid arthritis in Japanese patients, and the SAA1-13T allele in the 13T/C polymorphism on the 5'-flanking region of the SAA1 gene.
|
24593212 |
2014 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemotherapy and anti-inflammatory treatment for the disorders that underlie AL and AA amyloidosis are guided by serial measurements of the respective circulating amyloid precursor proteins, i.e. serial serum free light chains in AL and serum amyloid A protein in AA type.
|
22402917 |
2012 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The contributions of ageing, inflammatory activity, SAA1 exon 3 polymorphism as well as gender to the pathogenesis of AA amyloidosis in 144 cases were also studied by multiple regression analysis.
|
21627560 |
2011 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We treated 14 RA patients who had serum amyloid A protein (SAA) 1.3 allele, with biopsy-confirmed AA amyloidosis with etanercept and investigated the efficacy of etanercept treatment, focusing on renal function retrospectively.
|
20440529 |
2010 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This significant result indicates that a normal f-SAA will indicate a minimal or even absent risk of succumbing to AA amyloidosis.
|
19657764 |
2009 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AA amyloidosis invariably has been associated with fibrillar deposits of the acute phase high-density lipoprotein serum amyloid A isotypes SAA1 and SAA2.
|
20536400 |
2009 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Development of AA amyloidosis is rare in FMF patients without amyloidogenic single nucleotide polymorphisms (SNPs) (713T allele) of the SAA1 gene.
|
19339884 |
2009 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is suggested that SAA plays not only an important role in the development of AA amyloidosis but also interacts with events closely involved in metabolic syndrome as a high- and low-grade inflammatory modulator, respectively.
|
18369528 |
2008 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis.
|
17968686 |
2007 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis.
|
17039310 |
2006 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results of the analysis of real data indicated that a significant association between haplotypes in the SAA1 gene and AA-amyloidosis phenotype was observed in patients with rheumatoid arthritis, thereby suggesting the validity of the application of PENHAPLO for case-control data.
|
16980401 |
2006 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Another report revealed a strong association between SAA1 -13T/C and secondary amyloidosis in the rheumatoid arthritis patient group.
|
16874691 |
2006 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous reports have indicated that the -13T/C single nucleotide polymorphism (SNP) at the 5'-flanking region of SAA1 appears to be a better marker of AA-amyloidosis than the exon-3 based haplotype, i.e., SAA1.1 or SAA1.3, in both Japanese and American Caucasian populations.
|
16076608 |
2005 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that -13T is a genetic background for AA amyloidosis in both Japanese and Caucasians and the difference in prevalence of AA amyloidosis in the two ethnic groups may be due, at least in part, to a difference in the frequency of the -13T SAA1 allele.
|
12762135 |
2003 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the SAA1 -13T allele, rather than SAA1 exon 3 haplotypes, is primarily associated with AA amyloidosis risk.
|
11407685 |
2001 |
AA amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, the mean C-reactive protein (CRP) level during 2 years prior to the diagnosis of AA-amyloidosis was significantly higher in the patients with larger numbers of the gamma allele at the SAA1 locus (Spearman's correlation coefficient: 0.34, P<0.05).
|
10543406 |
1999 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that there is probably differential amyloidogenicity amongst the different SAA1 isoforms and indicate that homozygosity for SAA1 alpha and SAA1 gamma in the different populations is a significant risk factor for development of AA amyloidosis.
|
10036584 |
1998 |
AA amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronically elevated A-SAA concentrations are a prerequisite for the pathogenesis of secondary amyloidosis, a progressive and fatal disease characterized by the deposition in major organs of insoluble plaques composed principally of proteolytically cleaved A-SAA, and may also contribute to physiological processes that lead to atherosclerosis.
|
9729453 |
1998 |